| Dear Voornaam
Welcome to your weekly Cancer Research UK Research Update email.
In the past year, Cancer Research UK has made some big changes to the way in which we drive commercial innovation an important part of our new strategy to increase patient benefit arising from your research. In April, we launched Cancer Research Horizons, integrated our therapeutic innovation activities into one unit of over 200 drug discovery scientists, and set up a new seed fund and entrepreneurship programme. This will improve how we work so we can go further, faster, together.
The achievements over 2021 and 2022 speak to that ambition and demonstrate the extraordinary progress thats been made by Cancer Research Horizons, our industrial and academic partners and of course the Cancer Research UK-funded researchers who make it all possible. In our annual review, youll read about the latest drug Zynlonta weve had a hand in bringing to the market, and the 440m+ generated by our portfolio that enables us to reinvest in more cancer research. You'll learn more about our new spinout companies formed to foster a new class of cancer therapies or improve early cancer detection. And, youll find out about the various ways were supporting entrepreneurship through our Entrepreneurial Programme Initiatives.
Despite the ongoing challenges associated with the pandemic, we met with more than 330 principal investigators throughout 2021-22, often in a virtual setting, where researchers shared their discoveries and discussed how to translate them into patient benefit. We continue to work alongside the brightest minds and the best partners, to help us bring forward the day when all cancer is conquered.
Thank you to everyone we have partnered with we look forward to another great year ahead.
Kind regards,
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
FUNDING TO DEAL WITH UNCERTAINTY OVER HORIZON EUROPE ASSOCIATION The Science Minister announced up to 484m for the UK R&D sector to alleviate ongoing uncertainty over access to Horizon Europe and other EU programmes.
The package includes 100m for universities in England, with additional funding for the devolved administrations; 30m for a Talent and Research Stabilisation Fund a scheme initially announced under the Government's Horizon Europe 'Plan B' measures; and 200m to support UK research infrastructure.
The funding comes from the underspend of money allocated for Horizon association. It's encouraging to see that this funding stays in the R&D sector the tough fiscal environment led to fears it would be clawed back by the Treasury. The increase in quality-related research funding is particularly welcome and echoes one of our policy calls.
Alongside colleagues across the R&D sector, were clear that ongoing association with Horizon remains the priority. So, while the governments restatement of the UK's ambition to join Horizon was positive, there remains considerable uncertainty in this area. |
|
|---|
|
|---|
|
|
EXPERT ADVICE TO DEVELOP AND TARGET YOUR INNOVATION FOR THE MARKET Are you working on an innovative project and want to know more about how to translate your research into a commercially viable product?
Join Michael Salako, Start Codon Investment Director, Will Crone and Alex Hellawell from Innovia Technology at 10AM GMT on 8 December to hear their insights on how to pinpoint your customer, understand your competition, and develop a valuable product.
This is the fourth seminar in a five-part series of free, hybrid seminars included in a training scheme between Cancer Research Horizons and Start Codon to promote the development of new business ventures within oncology. |
|
|---|
|
|---|
|
|
IMPROVING PATIENT EXPERIENCE ACROSS CLINICAL TRIALS WITH TRIALMAP Our Centre for Drug Development has been working closely with the digital startup Stitch to develop Trialmap, an app which enables patients on clinical trials to provide feedback. Our goal is to optimise trial efficiency and design.
Stephen Nabarro, from our Centre for Drug Development, and members of our Patient Involvement Network, have reflected on the evolution of Trialmap and its potential for changing the experience of patients enrolled on clinical trials. |
|
|---|
| JOIN A COMMITTEE OF WORLD-LEADING CANCER EXPERTS If youre a highly experienced, prominent scientist or clinician, please consider joining our Discovery Research and Prevention and Population Research Committees and help us fund critical, cutting-edge cancer research.
We strongly encourage researchers with expertise applicable to both discovery and prevention research and researchers from underrepresented groups to apply. |
|
|---|
|
|---|
|
|
NEW POLICY TO EVOLVE CONTINUING PROFESSIONAL DEVELOPMENT Were formalising our commitments and expectations in our new policy for continuing professional development to further support the growth and progression of our researchers.
All host institutions are now expected to actively promote and fund career-based skills training opportunities, making sure these are embedded into research plans from the application stage. We also expect Cancer Research UK-funded researchers and students to dedicate 10 days each year (pro-rata if part-time) to continuing professional development. |
|
|---|
| PARTNERSHIP WITH THE KAROLINSKA INSTITUTE Our innovation engine, Cancer Research Horizons, has partnered with the world-leading Karolinska Institute to undertake a strategic five-year partnership dedicated to accelerating the translation of academic cancer research into improved treatments for patients. Together we will host joint events and training programmes, undertake funding initiatives, and build theme-based alliances.
The sharing of expertise, networks and collaboration partners to validate and translate novel targets and mechanisms are key features in this new partnership. Additionally, mutual access to research facilities is in the mix, for example researchers from the Karolinska will be able to bring their projects to the Cancer Research Horizons AstraZeneca Antibody Alliance Lab. |
|
|---|
|
|---|
|
|
| | | Birmingham, UK 9:30 AM 03 December 2022 |
|
|---|
|
|---|
| | | East Sussex, UK 04 December 2022 |
|
|---|
|
|---|
| | | Cambridge, UK 9:00 AM 10 February 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
